Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance

Description

This study will test the hypothesis that the molecular changes present in ectopic endometriosis lesions correlate with progesterone-resistant disease (using the criteria defined in this study) and are present in matched eutopic endometrium.

Conditions

Endometriosis, Endometrial Diseases

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will test the hypothesis that the molecular changes present in ectopic endometriosis lesions correlate with progesterone-resistant disease (using the criteria defined in this study) and are present in matched eutopic endometrium.

Prospective Clinical Study of the Relationship Between Cancer Driving Mutations Found in Endometriotic Implants and the Development of Progesterone Resistance

Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance

Condition
Endometriosis
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale School of Medicine, New Haven, Connecticut, United States, 06510

Baltimore

Johns Hopkins Hospital, Baltimore, Maryland, United States, 21218

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Signed informed consent.
  • * Gender: female.
  • * Age: 18-45 years at the time of signing consent.
  • * Clinical or surgical diagnosis of endometriosis undergoing laparoscopy.
  • * Controls may not have clinical or surgical diagnosis of endometriosis.
  • * Regular menstrual cycles.
  • * BMI between 18-40 kg/m2.
  • * Sexually active or have had a previous vaginal exam that used a speculum.
  • * English speaking
  • * Use of any kind of steroidal therapy including oral contraceptives, Norplant, estrogen replacement/supplemental therapy, androgens (Danazol, Cyclomen, Danocrine, testosterone) or progesterone. She may not be taking or be on Celebrex.
  • * Pregnant.
  • * Presence of pelvic infection.
  • * Mullerian anomalies with absence of a cervix.
  • * History of cancer of the reproductive tract.
  • * Presence of undiagnosed uterine bleeding.
  • * Treatment with intrauterine device (IUD) or progestin-containing intrauterine device.

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

James Segars, MD, FACOG, PRINCIPAL_INVESTIGATOR, Professor

Study Record Dates

2026-10-01